An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Avapritinib (Primary) ; Regorafenib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors Blueprint Medicines
- 13 Mar 2018 Status changed from planning to not yet recruiting.
- 07 Aug 2017 New trial record
- 02 Aug 2017 According to a Blueprint Medicines media release, the company is planning to initiate this trial in the first half of 2018.